ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Core Insights - ImmunityBio Inc has experienced a significant stock increase of nearly 96% year-to-date, driven by impressive revenue growth figures [1] - The company reported approximately $113 million in revenue for 2025, reflecting a remarkable 700% year-over-year increase, indicating strong commercial performance [2] - Fourth quarter revenue reached $38.3 million, up 431% year-over-year, primarily due to the rapid scaling of its lead oncology therapy, Anktiva [3] Revenue Growth and Market Position - Anktiva's growth trajectory is notable as it is scaling faster than many oncology treatments at a similar stage, shifting investor focus from trial risks to execution and demand [4] - Hedge funds like Renaissance Technologies and Citadel Advisors have made anticipatory investments based on the expected commercialization velocity of Anktiva, with Citadel increasing its stake by over 40% [5][6] - The substantial revenue growth prompts a reassessment of ImmunityBio's market position, transitioning from speculative biotech to a company with real sales acceleration [7]